Most things that BTX is working on are too far out to stave off dilution. Plus, there is another company that may have better cells for those printers you speak of. With Dr West working on so many great things I still like this company a lot. But, I won't be a buyer until something is closer to coming to market.
The blood cancer test won't be coming out for awhile, if ever, now that there is a potential patent issue here in the US.
The 10Q filed on 5.10.13 gave me serious pause. I searched it while trying to determine a hard date for a serious catalyst to the upside. I had been thinking that the cancer screening device might be the first thing to come to market.
The following are quotes related to the cancer screening device that I pulled out of the 10Q:
**********
"and the launch of PanC-Dx™ as a novel blood-based cancer screen, expected by 2014 in Europe."
**********
"Our subsidiary, OncoCyte Corporation, is developing PanC-Dx™, a novel non-invasive blood-based cancer screening test designed to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check -ups. We intend to initially seek regulatory approval to market PanC-Dx™ in Europe as a screen for breast cancer before seeking regulatory approvals required to market the product in the U.S. and other countries."
**********
"PanC-Dx™ is a trademark of OncoCyte Corporation."
**********
"The recent Supreme Court decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., will need to be considered in determining whether certain diagnostic methods can be patented, since the Court denied patent protection for the use of a mathematical correlation of the presence of a well-known naturally occurring metabolite as a means of determining proper drug dosage. Our subsidiary OncoCyte is developing PanC-Dx™ as a cancer diagnostic test, based on the presence of certain genetic markers for a variety of cancers. Because PanC-Dx™ combines an innovative methodology with newly discovered compositions of matter, we are hopeful that this Supreme Court decision will not preclude the availability of patent protection for OncoCyte’s new product. However, like other developers of diagnostic products, we are evaluating this new Supreme Court decision and new guidelines issued by the United States Patent and Trademark Office (the “PTO”) for the patenting of products that test for biological substances."
In Reply to 'nuketheshorts' Wall Street is all excited about Organovo lately. I wonder how long it will take those geniuses to realize that many other companies can also make 3d printers to squirt out human cells. But its really BioTime that deserves the recognition... because Biotime has the key to making the cells that the machine squirts into 3d layers!!
News 
Market Data 
Discover 
